ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein (1999)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 1999-07-27
    Description: Glycoprotein adhesion receptors such as selectins contribute to tissue injury in stroke. Ischemic neurons strongly expressed C1q, which may target them for complement-mediated attack or C1qRp-mediated clearance. A hybrid molecule was used to simultaneously inhibit both complement activation and selectin-mediated adhesion. The extracellular domain of soluble complement receptor-1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLex) to inhibit complement activation and endothelial-platelet-leukocyte interactions. sCR1 and sCR1sLex colocalized to ischemic cerebral microvessels and C1q-expressing neurons, inhibited neutrophil and platelet accumulation, and reduced cerebral infarct volumes. Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sCR1 molecule.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Huang, J -- Kim, L J -- Mealey, R -- Marsh, H C Jr -- Zhang, Y -- Tenner, A J -- Connolly, E S Jr -- Pinsky, D J -- R01 HL55397/HL/NHLBI NIH HHS/ -- R01 HL59488/HL/NHLBI NIH HHS/ -- R01 NS35144/NS/NINDS NIH HHS/ -- etc. -- New York, N.Y. -- Science. 1999 Jul 23;285(5427):595-9.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/10417391" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Blood Platelets/physiology ; Cell Adhesion ; Cerebral Cortex/blood supply/immunology/metabolism ; Cerebral Infarction/drug therapy ; Cerebrovascular Circulation ; Cerebrovascular Disorders/*drug therapy/immunology/physiopathology ; Complement Activation ; Complement C1q/metabolism ; Glycosylation ; Humans ; Ischemic Attack, Transient/*drug therapy/immunology/physiopathology ; Leukocytes/physiology ; Mice ; Neurons/immunology/metabolism ; Neuroprotective Agents/administration & dosage/adverse ; effects/metabolism/*therapeutic use ; Neutrophils/physiology ; Oligosaccharides/administration & dosage/adverse effects/metabolism/*therapeutic ; use ; Platelet Adhesiveness ; Receptors, Complement/administration & dosage/metabolism/*therapeutic use ; Reperfusion Injury/drug therapy/immunology/metabolism ; Selectins/metabolism ; Time Factors
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 2
    facet.materialart.
    Unknown
    Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis (1990)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 1990-07-13
    Description: The complement system is an important mediator of the acute inflammatory response, and an effective inhibitor would suppress tissue damage in many autoimmune and inflammatory diseases. Such an inhibitor might be found among the endogenous regulatory proteins of complement that block the enzymes that activate C3 and C5. Of these proteins, complement receptor type 1 (CR1; CD35) has the most inhibitory potential, but its restriction to a few cell types limits its function in vivo. This limitation was overcome by the recombinant, soluble human CR1, sCR1, which lacks the transmembrane and cytoplasmic domains. The sCR1 bivalently bound dimeric forms of its ligands, C3b and methylamine-treated C4 (C4-ma), and promoted their inactivation by factor I. In nanomolar concentrations, sCR1 blocked complement activation in human serum by the two pathways. The sCR1 had complement inhibitory and anti-inflammatory activities in a rat model of reperfusion injury of ischemic myocardium, reducing myocardial infarction size by 44 percent. These findings identify sCR1 as a potential agent for the suppression of complement-dependent tissue injury in autoimmune and inflammatory diseases.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Weisman, H F -- Bartow, T -- Leppo, M K -- Marsh, H C Jr -- Carson, G R -- Concino, M F -- Boyle, M P -- Roux, K H -- Weisfeldt, M L -- Fearon, D T -- New York, N.Y. -- Science. 1990 Jul 13;249(4965):146-51.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/2371562" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Autoimmune Diseases/*immunology/pathology ; Complement Activation ; Complement C3/antagonists & inhibitors ; Complement C3b Inactivator Proteins/pharmacology ; Complement C4b/antagonists & inhibitors ; Complement C5/antagonists & inhibitors ; Complement Inactivator Proteins/*pharmacology/ultrastructure ; Disease Models, Animal ; Myocardial Reperfusion Injury/*immunology/pathology/prevention & control ; Myocardium/*pathology ; Necrosis ; Rats ; Receptors, Complement/*pharmacology/ultrastructure ; Recombinant Proteins/pharmacology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...